Cell Therapy Catapult   Report issue

For profit Phase 2
Founded: London United Kingdom (2012)

Organization Overview

First Clinical Trial
2012
NCT01621724
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cell Therapy Catapult

Active Ingredients

Drugs in Phase 2 Trials (3)

multistem (1 trial)

somatic mesenchymal stromal cells (1 trial)

wt1 tcr-transduced t cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Fistula (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3